Implementation of fixed-dose combinations in tuberculosis control: outline of responsibilities
Abstract:Fixed-dose combinations (FDCs) of antituberculosis drugs have been available on the world market for more than forty years. For more than twenty years rifampicin-containing FDCs have become increasingly visible on the market in combinations of two, three and even four fixed-dose combinations, but in different dosages depending on the country and the region. As a result, instead of simplifying tuberculosis treatment and the application of standardised chemotherapy regimens, the situation has become progressively more complicated, and at the same time neither bioavailability nor patients' safety is guaranteed. It is time to rationalise and extend the use of FDCs in national tuberculosis programmes. International, supranational and national responsibilities must be clearly defined in this process.
Document Type: Regular Paper
Affiliations: Algiers, Algeria
Publication date: November 1, 1999
The International Journal of Tuberculosis and Lung Disease publishes articles on all aspects of lung health, including public health-related issues such as training programmes, cost-benefit analysis, legislation, epidemiology, intervention studies and health systems research. The IJTLD is dedicated to the continuing education of physicians and health personnel and the dissemination of information on tuberculosis and lung health world-wide.
Certain IJTLD articles are selected for translation into French, Spanish, Chinese or Russian. They are available on the Union website
- Editorial Board
- Information for Authors
- Subscribe to this Title
- International Journal of Tuberculosis and Lung Disease
- Public Health Action
- ingentaconnect is not responsible for the content or availability of external websites